News Kisqali set for approval - but likely to hit same NICE obsta... Concerns that NICE will reject Kisqali like it did Ibrance.
News Novartis' canakinumab cuts risk for heart attack survivors Novartis to discuss canakinumab results with regulators.
News Novartis next generation eye drug outperforms Eylea Brolucizumab could offer quarterly dosing schedule.
News Australia starts probe into AI infiltration of Medicare The infiltration of Australia's Medicare by an AI agent raises serious questions about patient privacy and the security of confidential pharma data.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
